31-45 of 158
When Itching Hurts: Quality of Life Disruption in CKD-aP
MinuteCE®When Itching Hurts: Quality of Life Disruption in CKD-aP
Nancy Helou, PhD
Steven Fishbane, MD
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
CME/CENo Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Brendon Neuen, MBBS, PhD
Katherine Tuttle, MD
Optimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
CME/CEOptimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
Jörg Latus, MD
Sayna Norouzi, MD
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
CME/CEEngaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CETranslating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Aldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
CME/CEAldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
Jamie P. Dwyer, MD
J. Matthew Luther, MD, MSCI
Vivek Bhalla, MD
- advertisement
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
CME/CEContinuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
Christian Mende, MD, FACP, FACN, FASN, FASH, FAHA
Deepak Bhatt, MD, MPH, MBA, FACC, FAHA
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
NephrologyOptimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Claudia Seikrit, MD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
CME/CEShifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Stephen J. Greene, MD
Anne Louise Peters, MD
- advertisement
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Hong Zhang
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®Emerging Evidence: IgAN Disease-Modifying Agents
Richard Lafayette, MD, FACP
Hong Zhang
